Lead Product(s): Aldesleukin
Therapeutic Area: Oncology
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Iovance Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2020
Proleukin will be made available by Clinigen in bulk supply over the course of a two-year period, ensuring that Iovance has uninterrupted access to Proleukin to continue ongoing clinical trials.